Women do not have an assigned place. Women are various. One size does not fit all.

In an attempt to protect poor, uninsured and underinsured Americans from unsafe drugs, we are making sure that some go without drugs completely. It is time the law was changed.

Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics, which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer.

Counterfeit drugs have contaminated India's pharmaceutical supply, putting the entire Indian medical system at risk, and can only be stopped by a broader political effort.

The proliferation of fake drugs is one of the greatest dangers facing India today, but the Indian government is touting a new study that is little more than a whitewash of this crucial problem.

"Phake: The Deadly World of Falsified and Substandard Medicines" explores the underground trade in illegal medicines that kills over 100,000 people per year and supplants billions of dollars of real products.

Risk Evaluation and Mitigation Strategies (REMS) are the newest tool of the FDA to help manage and ensure safe drug use. REMS are a particularly important issue for oncology, because a disproportionate number of drugs with complex REMS are used in patients with cancer or hematologic disorders.

India's continued rise as a pharmaceutical power is tainted by concerns about fake and substandard drugs, but a new report finds that private companies are finding innovative ways of preserving the identity of their products.